Baseline Biomarkers Associated With Clinical Benefit In Patients With Solid Tumors Refractory To Immune Checkpoint Inhibitors (Icis) Treated With Live Biotherapeutic Mrx0518 In Combination With Pembrolizumab

E. R. Parra, M. Adriani, C. Freitas Pinto Lima, J. Li, C. Haymaker,R. Parikh, E. Bernicker, D. Davar, A. Chaudhry, A. Stevenson, C. Badham, G. Fyvie, M. Chisamore,S. Pant

ANNALS OF ONCOLOGY（2021）

引用 1|浏览1